Park Dental Partners, Inc. PARK PHARMA
Company Overview
Park Dental Partners, Inc. operates as a dental resource organization that provides administrative business support services to dentists in Minnesota, Wisconsin, and Arizona. The company offers general and specialty dental care services, such as dentist and hygiene, oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics. It provides clinical team members, administrative personnel, and facilities and equipment to its affiliated general and multi-specialty dental practices. The company was founded in 1972 and is headquartered in Roseville, Minnesota.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +5.1%, earnings -84.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 5.10% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -84.80% |
Stock Price Performance
| 1 Year: | +96.88% |
| 6 Months: | +8.49% |
| 3 Months: | +12.30% |
| 1 Month: | -4.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)46.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PARK Park Dental Partners, Inc. PHARMA | 20.18 | -26.91 | $95.96M | 0.00% | 0.18% | -24.16% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 59.04M | 63.00M | 61.25M | 61.21M | 62.70M |
| Cost of Revenue | 49.18M | 51.09M | 51.81M | 58.74M | 56.31M |
| Gross Profit | 9.86M | 11.91M | 9.44M | 2.47M | 6.38M |
| Operating Expenses | 7.31M | 7.75M | 7.65M | 10.71M | 8.26M |
| Operating Income | 2.55M | 4.15M | 1.78M | -8.23M | -1.88M |
| EBITDA | 4.82M | 6.49M | 4.17M | -5.86M | 503.00K |
| Interest Expense | 337.00K | 334.00K | 259.00K | 240.00K | 121.00K |
| Pretax Income | 2.21M | 3.82M | 1.52M | -8.47M | -2.00M |
| Tax Provision | 646.00K | 1.25M | 274.00K | -2.73M | -1.61M |
| Net Income | 1.57M | 2.57M | 1.25M | -5.75M | -390.00K |
| Diluted EPS | 0.38 | - | - | -2.31 | -0.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | - | - | 244.49M |
| Cost of Revenue | - | - | 210.82M |
| Gross Profit | - | - | 33.67M |
| Operating Expenses | - | - | 33.42M |
| Operating Income | - | - | 250.00K |
| EBITDA | - | - | 9.63M |
| Interest Expense | - | - | 1.17M |
| Pretax Income | - | - | -920.00K |
| Tax Provision | - | - | -562.00K |
| Net Income | - | - | -358.00K |
| Diluted EPS | 1.19 | 1.07 | -0.18 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | - | 178.18M |
| Current Assets | - | - | 37.90M |
| Cash & Equivalents | - | - | 25.18M |
| Inventory | - | - | 930.00K |
| Receivables | - | - | 6.99M |
| Total Liabilities | - | - | 156.38M |
| Current Liabilities | - | - | 35.73M |
| Long Term Debt | - | - | 10.09M |
| Total Debt | - | - | 60.35M |
| Total Equity | - | - | 21.80M |
| Shares Outstanding | 4.09M | 4.09M | 4.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | 17.63M |
| Investing Cash Flow | -10.65M |
| Financing Cash Flow | 15.53M |
| Capital Expenditure | -7.34M |
| Free Cash Flow | 10.29M |
| Net Change in Cash | 22.51M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | 13.8% |
| Operating Margin % | - | - | 0.1% |
| Net Margin % | - | - | -0.1% |
| ROE % | - | - | -1.6% |
| ROCE % | - | - | 0.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kennedy Capital Management, LLC | 4.98% | 236.81K | $4.82M |
| 2 | Heartland Advisors Inc. | 4.21% | 200.00K | $4.07M |
| 3 | Pacific Ridge Capital Partners, LLC | 3.63% | 172.75K | $3.51M |
| 4 | Russell Investments Group, Ltd. | 1.85% | 88.16K | $1.79M |
| 5 | Punch & Associates Investment Management, Inc. | 1.41% | 67.02K | $1.36M |
| 6 | Vanguard Capital Management LLC | 1.40% | 66.42K | $1.35M |
| 7 | Citadel Advisors Llc | 1.12% | 53.45K | $1.09M |
| 8 | Access Financial Services, Inc. | 1.04% | 49.69K | $1.01M |
| 9 | Royal Bank of Canada | 0.94% | 44.46K | $904.40K |
| 10 | Marshall Wace LLP | 0.52% | 24.75K | $503.52K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PARK
Should You Buy Park Stock After Its 61% Rally in a Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPYlhkc1VPejFYWlBQVmVqNWJkeEhZUDVUOWRTdkNUWUdJeTFCSV9NS0YweDFLOE9RT0QzVHpPcGgtajZ4dV96bm82ZXY2RkFwTEtuY0JqSzVJMFI5bF8zZWNCS2FJeTFhb3ZISXdIX2Q2VFBmVHg4aVpJWGdqRnNmRXRvMEZmY21sVEM5WE…
Should Value Investors Buy Park-Ohio (PKOH) Stock? - qz.com
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE0ya2ZiNU1RZUVwcDFMTktBQTJ0QnY0a01nWUtZYWtJZGpXNVZyU29PX1VEOXRNdUhGVHFGN3Jhd2U2azJSbFZmdi1hRHVzN1Z6R0ZyMlVxeEpVVW9qVW50aEhOaGhqUi1SR3F5QXFXaw?oc=5" target="_blank">Should Value Inve…
Canterbury Park (NASDAQ:CPHC) Stock Price Passes Above 200-Day Moving Average - What's Next? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxONzBhb3V1UTJpdGlmVDVnamEyaTdCR0NuNzhZMWFtTFB5U040ckNTZWN2UkVpQlhaanlSbkZmMzJ5ZHJ1RkJfOXdscmluUXZmTTNCeTFvWHpsM2ktbVVSbk1qemRKUDFLaFA3bkU0TWZHRXo4RHR3eDA1UnJiLW5ZUDMydWpOZlF6LTRHaX…
BYAH Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Park Ha Biological Technology Co, Ltd - TMX Newsfile
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxPZFZWRVp0aS1MUmpmSFJRNzF5aEp1cm0zdGVfaHVYZXlKZF9qLXBCOEtGMERDVkxwc1gwZ2tiQmRXVmFlYTZzTlcxYW9fdnZxQ1luQU1yTW1ZN3V5c2lqVDNGTzgwMDNDSjJzeHBfOUR6RTBYeThWQXE5SUY5aUFWUEh1SEJiRmFpblprcW…
Park Electrochemical Stock Price Forecast. Should You Buy PKE? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE1VNXhoUHFJc1lqVlB4dWdzeGR1bGZQYzBUNFM3RGh0TXZ1WWkyNmh6ZFdieUxtM0lTd0x6bnprVEdEMFdKUGFz?oc=5" target="_blank">Park Electrochemical Stock Price Forecast. Should You Buy PKE?</a> …
Stock Available for Adoption - National Park Service (.gov)
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE1aYWsyRVk1SFlWWURibnFJT0kwRExROWVnVWEzNTFucHAxd1BkT2hTMFRxTE1YTU5aazlxa2E5OV90UHMzOTJqa3JVeF8zbUhCRHgwbW50X1lubzM0alBxYzVBNzg?oc=5" target="_blank">Stock Available for Adoption</a>…
PARK — Frequently Asked Questions
What is the current share price of Park Dental Partners, Inc. (PARK)?
As of 2026-09-19 21:16 PDT, Park Dental Partners, Inc. (PARK) trades at $20.18 on NasdaqCM. Its 52-week range is $10.25 to $23.05.
What is the market capitalisation of PARK?
Park Dental Partners, Inc. (PARK) has a market capitalisation of $95.96M on NasdaqCM.
What is the P/E ratio of PARK?
PARK trades at a trailing price-to-earnings (P/E) ratio of -26.91. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.21.
What is the return on equity (ROE) of PARK?
PARK has a return on equity (ROE) of -24.16%. Its return on capital employed (ROCE) is 0.18%.
Is PARK a good stock to buy?
This page provides a data-driven analysis of Park Dental Partners, Inc. (PARK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.